Travere Good Will from 2010 to 2025
| TVTX Stock | USD 20.53 0.30 1.44% |
Good Will | First Reported 2014-03-31 | Previous Quarter 747 K | Current Value 800 K | Quarterly Volatility 56.5 K |
Check Travere Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Travere Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 16.1 M, Selling General Administrative of 277.3 M or Other Operating Expenses of 584.9 M, as well as many indicators such as Price To Sales Ratio of 6.84, Dividend Yield of 0.0 or PTB Ratio of 22.1. Travere financial statements analysis is a perfect complement when working with Travere Therapeutics Valuation or Volatility modules.
Travere | Good Will |
Latest Travere Therapeutics' Good Will Growth Pattern
Below is the plot of the Good Will of Travere Therapeutics over the last few years. It is an intangible asset that arises when a company acquires another business for more than the fair market value of its net identifiable assets, representing the value of the brand, customer base, and other intangible factors. Travere Therapeutics' Good Will historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Travere Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Good Will | 10 Years Trend |
|
Good Will |
| Timeline |
Travere Good Will Regression Statistics
| Arithmetic Mean | 900,478 | |
| Geometric Mean | 897,482 | |
| Coefficient Of Variation | 8.03 | |
| Mean Deviation | 53,242 | |
| Median | 935,935 | |
| Standard Deviation | 72,328 | |
| Sample Variance | 5.2B | |
| Range | 213K | |
| R-Value | (0.71) | |
| Mean Square Error | 2.8B | |
| R-Squared | 0.50 | |
| Significance | 0 | |
| Slope | (10,731) | |
| Total Sum of Squares | 78.5B |
Travere Good Will History
About Travere Therapeutics Financial Statements
Travere Therapeutics investors use historical fundamental indicators, such as Travere Therapeutics' Good Will, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Travere Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Good Will | 800 K | 723 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.